cpcph
rel
common
complic
chronic
hf
associ
poor
surviv
specif
pharmacolog
treatment
stimul
shown
improv
pulmonari
hemodynam
rv
perform
translat
larg
anim
model
mimick
condit
spherehf
trial
phase
ii
random
doubleblind
clinic
trial
design
evalu
efficaci
safeti
mirabegron
oral
ar
agonist
patient
cpcph
secondari
hf
spherehf
trial
includ
patient
treat
mirabegron
placebo
week
main
outcom
chang
pvr
secondari
outcom
includ
chang
rv
perform
clinic
statu
ntprobnp
level
addit
pulmonari
hemodynam
paramet
combin
preand
postcapillari
hypertens
cpcph
rel
common
complic
heart
failur
hf
associ
poor
prognosi
current
specif
therapi
approv
entiti
recent
treatment
adrenerg
receptor
agonist
abl
improv
pulmonari
hemodynam
right
ventricular
rv
perform
translat
larg
anim
model
chronic
ph
author
present
design
phase
ii
random
clinic
trial
test
benefit
mirabegron
clinic
avail
agonist
patient
cpcph
due
hf
effect
treatment
evalu
pulmonari
hemodynam
well
clinic
biochem
advanc
cardiac
imag
paramet
result
sever
symptom
wors
exercis
toler
increas
risk
death
initi
isol
postcapillari
ph
ipcph
pure
passiv
potenti
progress
combin
preand
postcapillari
ph
cpcph
progress
diseas
character
signific
vasoconstrict
vascular
remodel
wors
prognosi
ipcph
although
ipcph
treat
focus
underli
condit
cpcph
requir
treatment
pulmonari
vascular
remodel
primari
heart
diseas
current
specif
pharmacolog
therapi
approv
patient
cpcph
clinic
studi
perform
specif
pulmonari
vasodil
ie
prostanoid
endothelin
receptor
blocker
cohort
hf
ph
secondari
hf
shown
posit
result
primarili
concomit
system
hypotens
hepat
toxic
although
preliminari
data
small
singlecent
studi
test
phosphodiesteras
type
inhibitor
ph
secondari
hf
promis
recent
evid
strongli
discourag
use
set
addit
neutral
find
report
cyclic
guanosin
monophosph
cgmp
stimul
ph
secondari
hf
either
preserv
reduc
left
ventricular
eject
fraction
lvef
therefor
new
treatment
need
cpcph
sympathet
nervou
system
central
neurohumor
regul
cardiovascular
function
implic
mani
cardiopulmonari
diseas
like
adrenoreceptor
coupl
g
protein
downstream
activ
pathway
includ
nitric
oxid
synthas
nitric
oxideactiv
guanylyl
cyclas
cgmp
synthesi
well
increas
cyclic
adenosin
monophosph
synthesi
loss
cgmp
cyclic
adenosin
monophosph
signal
repres
hallmark
ph
known
within
pulmonari
circul
cyclic
nucleotid
exert
sever
favor
effect
includ
vasodilat
inhibit
smooth
muscl
cell
prolifer
prevent
platelet
aggreg
recent
year
sever
public
demonstr
cardioprotect
effect
stimul
differ
experiment
model
ischemiareperfus
injuri
hf
therefor
emerg
potenti
thera
tabl
first
protocol
exclus
criterium
qtc
interv
ecg
ms
men
women
includ
gener
safeti
standard
criterion
later
modifi
amend
qtc
particip
assign
individu
basi
mirabegron
placebo
use
randomli
select
block
size
stratifi
center
use
blockrand
packag
r
foundat
random
list
provid
exclus
pharmaci
depart
respons
medic
prepar
inform
consent
x
prepar
medic
kit
identifi
uniqu
sequenti
number
entir
studi
provid
kit
center
research
assign
receiv
medic
kit
sequenti
order
record
kit
number
provid
patient
data
collect
system
baselin
descript
statist
calcul
accord
standard
method
itt
pp
popul
qualit
variabl
describ
absolut
number
n
frequenc
wherea
quantit
variabl
describ
mean
ae
sd
normal
bp
systol
bp
mm
hg
hr
beatsmin
qtc
interv
ms
men
ms
women
blood
analysi
within
normal
patient
asymptomat
titrat
studi
medic
mgday
patient
develop
follow
signific
hypotens
systol
bp
mm
hg
hypertens
systol
bp
mm
hg
tachycardia
hr
beatmin
prolong
qtc
interv
ms
men
ms
women
worsen
renal
functiontransaminas
elev
blood
analysi
symptom
associ
medic
median
interquartil
rang
depend
normal
assess
use
shapirowilk
test
efficaci
measur
calcul
itt
pp
analys
treatment
effect
primari
outcom
measur
analyz
use
linear
regress
model
includ
baselin
valu
treatment
baselin
treatment
interact
center
center
treatment
interact
interact
term
remov
wald
test
statist
signific
p
efficaci
analys
done
pp
set
consid
confirmatori
main
analys
itt
popul
case
miss
final
valu
primari
outcom
measur
valu
replac
baselin
data
last
observ
carri
forward
follow
exploratori
analys
primari
outcom
measur
contempl
lvef
lvef
vs
maximum
toler
dose
mgd
subgroup
interact
treatment
secondari
outcom
measur
analyz
similarli
use
linear
model
quantit
normal
variabl
gener
model
quantit
nonnorm
variabl
logist
regress
dichotom
valu
analysi
secondari
variabl
carri
use
avail
inform
without
miss
imput
techniqu
descript
analysi
perform
evalu
safeti
treatment
use
safeti
popul
interim
analys
plan
p
valu
consid
statist
signific
unless
otherwis
specifi
examin
r
g
h
h
e
r
c
h
e
e
r
z
n
procedur
perform
use
swanganz
cathet
introduc
via
intern
jugular
vein
use
standard
methodolog
hemodynam
measur
includ
right
atrial
pressur
systol
diastol
mean
pap
well
pulmonari
capillari
wedg
pressur
endexpir
zero
level
set
level
anterior
axillar
line
lie
flat
differ
mean
pap
valu
regist
period
averag
calcul
cardiac
output
quantifi
thermodilut
method
measur
averag
exclud
highest
lowest
valu
n
w
l
k
n
g
e
test
carri
follow
recommend
american
european
respiratori
societi
patient
instruct
walk
along
long
corridor
walk
far
possibl
min
test
supervis
nurs
heart
rate
oxygen
satur
record
cardiomyopathi
questionnair
valid
spanish
popul
use
assess
qualiti
life
p
h
c
l
e
x
n
n
blood
pressur
measur
everi
visit
use
autom
sphygmomanomet
quiet
room
three
measur
perform
period
averag
second
third
measur
regist
heart
rate
oxygen
satur
use
puls
oxymet
also
enter
electron
case
report
form
patient
weigh
everi
studi
visit
function
class
follow
nyha
classif
well
hf
sign
symptom
record
b
l
p
l
e
venou
sampl
obtain
visit
test
complet
blood
count
serum
glucos
well
renal
liver
function
ntprobnp
measur
also
perform
visit
e
c
g
heart
rhythm
heart
rate
qt
qtc
interv
measur
c
r
n
l
cine
flow
imag
delay
enhanc
analyz
use
special
softwar
intellispaceport
philip
blind
investig
imag
core
laboratori
cnic
cine
imag
enddiastol
endsystol
frame
select
base
visual
assess
largest
smallest
lv
volum
respect
open
close
atrioventricular
semilunar
valv
biventricular
endocardi
contour
manual
trace
enddiastol
endsystol
simpson
method
use
automat
calcul
enddiastol
volum
endsystol
volum
eject
fraction
rv
trabecul
adjud
blood
pool
figur
similarli
inner
contour
main
pulmonari
arteri
cross
section
outlin
cardiac
phase
integr
pulmonari
arteri
area
flow
follow
paramet
quantifi
peak
veloc
averag
veloc
complet
cardiac
cycl
minimum
maximum
area
pulmonari
arteri
net
forward
volum
rvarteri
coupl
ratio
pulmonari
arteri
effect
elast
rv
maxim
endsystol
elast
estim
endsystol
volumestrok
volum
region
interest
drawn
map
myocardi
anterior
inferior
rv
insert
point
interventricular
septum
lv
later
wall
lv
caviti
blood
pool
contrast
administr
estim
extracellular
volum
previous
describ
figur
p
r
l
ph
associ
hf
repeatedli
shown
decreas
surviv
particularli
patient
cpcph
although
ipcph
entir
revers
pulmonari
arteri
wedg
pressur
normal
medic
surgic
intervent
case
cpcph
due
associ
pulmonari
arteri
remodel
latter
correl
pulmonari
vascular
gradient
increas
pvr
approxim
patient
ph
hf
present
cpcph
preval
similarli
distribut
reduc
preserv
hf
underlin
van
derpool
naeij
knowledg
specif
phenotyp
cpcph
great
import
design
futur
trial
target
therapi
ph
hf
sever
random
control
trial
test
effect
pulmonari
vasodil
hf
focus
patient
confirm
ph
minor
studi
focus
cpcph
studi
evalu
effect
prostanoid
epoprostenol
receptor
antagonist
bosentan
patient
advanc
hf
sever
lv
systol
dysfunct
termin
earli
due
increas
rate
advers
event
investig
drug
group
compar
control
group
recent
melodi
macitentan
pulmonari
hypertens
due
left
ventricular
dysfunct
trial
random
patient
cpcph
macitentan
placebo
differ
main
endpoint
composit
fluid
retent
worsen
nyha
function
class
group
phosphodiesterasetyp
inhibitor
also
fail
show
consist
effect
ph
secondari
hf
moreov
recent
spanish
multicent
siovac
sildenafil
improv
outcom
valvular
correct
trial
includ
patient
residu
ph
surgic
treat
valvular
heart
diseas
sildenafil
associ
wors
outcom
placebo
regard
solubl
guanyl
cyclas
stimul
riociguat
neutral
find
report
ph
secondari
hf
preserv
reduc
lvef
sever
limit
previou
trial
note
target
popul
select
base
pulmonari
hemodynam
statu
confirm
diagnosi
ph
includ
full
spectrum
patient
lhd
minor
target
patient
cpcph
studi
singl
center
mortal
undertaken
garcialunar
et
al
recogn
guidelinedirect
histolog
grade
endomyocardi
biopsi
tissu
sampl
reject
surveil
limit
diagnost
accuraci
quantit
situ
character
perform
sever
import
immun
cell
type
retrospect
cohort
clinic
endomyocardi
tissu
sampl
differ
case
identifi
group
histolog
grade
versu
clinic
reject
trajectori
significantli
increas
program
death
ligand
forkhead
box
cluster
differenti
cell
suppress
clinic
evid
reject
especi
case
mark
clinicalhistolog
discord
program
death
ligand
forkhead
box
cluster
differenti
cell
proport
also
significantli
higher
neverreject
compar
futurereject
find
suggest
unfortun
guidelinerecommend
ishlt
grade
scheme
suffer
lack
prognost
accuraci
correl
poorli
clinic
trajectori
current
reject
event
lack
abil
stratifi
patient
futur
car
risk
improv
diagnost
accuraci
reject
risk
stratif
inflammatori
infiltr
extract
addit
clinic
relev
inform
emb
sampl
despit
call
action
limit
applic
tissuelevel
immun
phenotyp
human
heart
transplant
tissu
stand
contrast
oncolog
rheumatolog
medicin
deeper
phenotyp
immun
popul
immun
effector
pathway
result
improv
risk
stratif
better
target
therapeut
strategi
paper
report
novel
proofofconcept
studi
appli
stateoftheart
fulli
quantita
specif
cohort
transplant
emb
describ
paper
select
permit
assess
immun
cell
popul
differ
tissu
low
versu
high
ishlt
grade
tissu
correspond
clinic
silent
versu
clinic
evid
reject
trajectori
tissu
patient
go
experi
seriou
reject
futur
reject
versu
never
reject
retrospect
chart
review
analysi
archiv
tissu
specimen
employ
research
approv
institut
review
board
univers
pennsylvania
retrospect
case
ishlt
histolog
grade
assign
attend
pathologist
time
emb
procedur
use
refer
standard
reject
diagnosi
grade
simplifi
assign
binari
histolog
grade
label
lowgrad
reject
defin
ishlt
consensu
criteria
histolog
grade
highgrad
reject
defin
ishlt
histolog
grade
group
typic
defin
distinct
use
determin
whether
augment
immunosuppress
therapi
prescrib
emb
event
distinct
clinic
silent
clinic
evid
reject
made
base
set
major
minor
criteria
determin
whether
allograft
injuri
present
clinic
metadata
within
day
emb
event
collect
allow
determin
clinic
trajectori
data
deriv
electron
health
recorddocu
symptom
physic
exam
find
lab
result
echocardiograph
paramet
electrocardiogram
find
invas
hemodynam
data
major
criteria
tabl
differenti
clinic
evid
clinic
silent
reject
trajectori
base
definit
hemodynam
compromis
previou
prospect
investig
allograft
reject
provid
high
specif
clinic
signific
reject
minor
criteria
tabl
final
emb
cohort
categor
low
ishlt
grade
clinic
silent
classifi
patientlevel
incid
futur
seriou
car
event
emb
assign
binari
label
either
futur
reject
never
reject
base
whether
seriou
car
event
occur
within
first
year
posttransplant
case
allow
assess
whether
corp
radnor
pennsylvania
use
immunohistochemistri
section
per
slide
cut
unstain
tissu
section
store
nitrogen
chamber
minim
oxid
degrad
tissu
epitop
addit
emb
slide
slide
nativ
nontranspl
heart
tissu
obtain
cadaver
organ
donor
slide
human
lymph
node
tissu
use
neg
posit
stain
control
respect
cytotox
tcell
marker
select
due
recognit
cell
popul
primari
effector
myocyt
injuri
cellular
reject
regulatori
tcell
transcript
factor
select
due
immunemodulatori
antiinflammatori
effect
transform
growth
factorbsecret
cell
thought
exert
renal
allograft
anim
model
heart
transplant
monocyt
lineag
marker
use
diagnosi
antibodymedi
reject
also
implic
cellular
reject
albeit
conflict
result
effect
cell
exert
final
compon
immun
checkpoint
molecul
interact
suppress
cytotox
action
activ
cell
though
checkpoint
inhibitor
use
cancer
immunotherapi
implic
myocard
role
checkpoint
molecul
human
heart
transplant
includ
case
report
sever
reject
follow
oncolog
inhibitor
treatment
annot
sampl
conduct
quantit
imag
analysi
sampl
unabl
yield
region
interest
due
confound
factor
tissu
fold
small
tissu
biopsi
size
larg
area
without
myocardium
eg
vessel
fibrosi
fat
q
u
n
v
e
u
l
p
e
c
r
l
g
e
n
l
spectral
librari
creat
stain
librari
slide
autofluoresc
spectrum
isol
use
autofluoresc
slide
annot
region
interest
import
new
project
inform
tissu
finder
akoya
bioscienc
spectral
unmix
use
gener
spectral
librari
note
imag
analyst
blind
slide
cohort
categori
avoid
bia
flow
diagram
depict
studi
cohort
subgroup
car
cardiac
allograft
reject
emb
endomyocardi
biopsi
ishlt
intern
societi
heart
lung
transplant
qc
qualiti
control
peyster
et
al
tabl
even
strike
cell
abund
clinic
silent
case
compar
clinic
evid
case
regardless
ishlt
grade
tabl
figur
highlight
strong
gradeindepend
correl
immunophenotyp
futureand
neverreject
case
assess
whether
immun
phenotyp
differ
patient
suffer
import
reject
event
futur
analyz
subset
case
serial
concor
despit
rel
case
everi
qmif
marker
except
display
statist
signific
differ
futurereject
case
neverreject
case
shown
tabl
though
analys
perform
biopsi
uniformli
lowhistolog
grade
time
evid
allograft
dysfunct
injuri
futurereject
group
close
resembl
clinic
evid
highgrad
reject
group
clinic
silent
lowgrad
group
futurereject
group
analyz
tempor
proxim
incid
sever
reject
event
appar
progress
emerg
compar
neverreject
case
futurereject
case
month
prior
reject
moder
reduc
proport
cell
week
clinic
evid
reject
dramat
statist
signific
dropoff
extrem
low
level
cell
tabl
figur
proofofconcept
studi
appli
qmif
technolog
within
cardiac
transplant
popul
provid
compel
evid
feasibl
util
immun
phenotyp
improv
diagnost
prognost
valu
allograft
emb
specimen
first
use
archiv
formalinfix
paraffinembed
tissu
blockssom
peyster
et
al
tabl
figur
peyster
et
al
overal
qmif
result
emb
case
group
clinic
trajectori
support
hypothesi
accur
assess
threat
allograft
function
imag
discord
low
ishlt
grade
emb
lowhistolog
grade
clinic
evid
allograft
injuri
imag
discord
high
ishlt
grade
emb
c
concord
high
ishlt
grade
emb
although
rough
estim
basophil
cellular
infiltr
due
appear
markedli
differ
within
grade
h
e
slide
vs
vs
multiplex
profil
within
grade
visibl
differ
case
without
evid
allograft
injuri
note
diffus
green
stain
within
myocardium
patient
clinic
silent
car
comparison
clinic
evid
car
also
note
profound
within
cellular
infiltr
discord
highgrad
emb
well
higher
proport
albeit
overal
low
densiti
cell
compar
concord
high
grade
emb
vs
scale
bar
um
panel
row
c
um
panel
row
b
phrase
differ
panel
row
c
um
total
width
panel
row
b
um
total
width
dapi
abbrevi
figur
abbrevi
tabl
focu
signific
biomed
research
though
rare
context
organ
transplant
bind
helper
cell
beyond
simpl
inactiv
consequ
decreas
inflammatori
cytokin
product
shown
stimul
express
effector
tcell
differenti
regulatori
cell
peyster
et
al
marguli
uphsupennedu
go
http
wwwaccorg
jaccjournalscm
take
cmemocecm
quiz
articl
surprisingli
could
reproduc
observ
realtim
thrombu
format
within
minut
without
treatment
chemic
agent
thrombu
induct
figur
video
indic
observ
fluoresc
microscopi
trigger
thrombu
format
ligat
femor
saphen
vein
also
confirm
thrombu
form
femal
mice
icr
mice
strain
albino
mice
manner
n
respect
indic
thrombu
induct
sex
strain
melamineindepend
data
shown
hypothes
thrombu
format
tabl
plateletand
neutrophildeplet
prevent
thrombu
format
chang
thrombu
size
acut
p
ns
respect
figur
neutrophil
extracellular
trap
also
report
key
player
dvt
initi
howev
pretreat
deoxyribonucleas
also
affect
dvt
size
model
figur
oxid
stress
consid
major
contributor
format
dvt
model
laser
figur
might
explain
dvt
exhibit
annual
ringlik
structur
also
observ
leukocyt
migrat
dvt
accompani
platelet
recent
studi
report
vivo
thrombosi
imag
system
avail
highresolut
microscop
imag
howev
thrombu
model
injuryinduc
laserinduc
electrolyt
platelet
thrombusbas
fibrinand
erythrocyterich
thrombu
visual
studi
furthermor
model
use
small
vessel
cremast
muscl
mesenteri
vessel
microvascular
thrombosi
model
relat
patholog
thrombu
occur
sepsi
inflammatori
disord
relev
larg
vessel
jugular
femor
vein
observ
human
vte
term
thrombu
induct
stage
microscopi
model
similar
convent
laserinduc
vivo
imag
model
howev
succeed
thrombu
induct
femoralsaphen
vein
liter
deep
vein
oppos
cremast
mesenter
arteriol
previou
laserinduc
model
second
use
filter
white
light
mainli
fitc
filter
microscop
produc
mercuri
lamp
nitrogen
heliumneon
laser
use
past
studi
believ
weaker
light
stimul
larger
vein
size
reason
thrombu
could
form
light
irradi
alon
form
thrombu
plateletrich
thrombu
recent
studi
succeed
appli
ivc
ste
phosphorylcholin
proinflammatori
epitop
atherogen
oxid
phospholipid
studi
investig
effect
novel
monoclon
antibodi
pc
vascular
function
atherosclerot
inflamm
treatment
phosphorylcholin
antibodi
preserv
coronari
flow
reserv
decreas
uptak
ffdg
atherosclerot
lesion
hypercholesterolem
mice
noninvas
imag
techniqu
repres
translat
tool
assess
efficaci
phosphorylcholinetarget
therapi
coronari
arteri
function
atherosclerosi
studi
show
treatment
therapeut
monoclon
antibodi
phosphorylcholin
oxid
phospholipid
preserv
coronari
flow
reserv
attenu
atherosclerot
inflamm
determin
uptak
tabl
treatment
well
toler
antibodi
remain
present
blood
end
intervent
averag
plasma
concentr
day
last
inject
ae
mgml
one
mous
exclud
due
failur
dose
detect
level
plasma
mous
due
failur
dose
ffdg
thu
final
studi
group
consist
mice
vehicl
group
mice
group
shown
tabl
figur
respect
nonspecif
igg
figur
geneexpress
tend
lower
presenc
pcmab
nonspecif
igg
statist
signific
geneexpress
well
protein
level
similar
presenc
pcmab
nonspecif
igg
antibodi
figur
tabl
result
reveal
treatment
exogen
antibodi
target
pc
epitop
oxpl
preserv
cfr
reduc
patient
stabl
coronari
arteri
diseas
level
pc
epitop
ldl
particl
shown
significantli
relat
sever
endotheli
dysfunct
lipidlow
therapi
furthermor
neg
correl
oxldl
level
cfr
integr
measur
coronari
reactiv
found
young
individu
hypercholesterolemia
result
extend
previou
find
despit
reduc
ffdg
uptak
find
reduct
overal
lesion
macrophag
quantiti
proport
polar
macrophag
lesion
collagen
content
atherosclerosi
burden
base
previou
valid
studi
mice
show
extens
preexist
atherosclerosi
begin
therapi
studi
therefor
unlik
major
plaqu
regress
chang
plaqu
cellular
composit
would
occur
within
shortterm
treatment
previou
studi
indic
metabol
marker
ffdg
uptak
sensit
chang
caus
shortterm
intervent
despit
chang
plaqu
burden
aortic
ffdg
signal
provid
independ
predictor
futur
cardiovascular
event
also
region
differ
drive
forc
atherogenesi
mice
although
histolog
analyz
aortic
root
tsiantoula
meduniwienacat
combin
chd
phenotypedriven
gene
set
enrich
crispr
knockdown
screen
zebrafish
effect
approach
identifi
novel
chd
gene
mutat
affect
gene
code
protein
complex
small
gtpasemedi
signal
associ
lvoto
lesion
complex
gene
regul
small
gtpase
signal
critic
zebrafish
heart
develop
genet
variant
primari
driver
congenit
heart
diseas
chd
pathogenesi
howev
abil
identifi
caus
variant
limit
identifi
causal
chd
gene
associ
specif
molecular
function
studi
use
prior
knowledg
filter
de
novo
variant
proband
sporad
sever
chd
approach
enabl
author
identifi
associ
left
ventricular
outflow
tract
obstruct
lesion
gene
associ
complex
regul
small
gtpasemedi
signal
transduct
use
crispr
zebrafish
knockdown
studi
confirm
complex
protein
three
independ
analysi
pipelin
use
process
read
map
use
tabl
lvoto
highestrank
corum
protein
complex
identifi
enrichr
one
gobp
term
consist
enrich
use
tool
regul
small
gtpasemedi
signal
transduct
tabl
therefor
select
complex
gene
valid
zebrafish
embryo
gene
set
enrich
perform
use
hhe
mgi
librari
silicofilt
gene
hypergeometr
overrepresent
test
implement
use
enrichr
webgestalt
term
filter
statist
signific
benjaminihochbergadjust
p
use
tool
combin
score
deriv
enrichr
uniqu
rank
system
combin
adjust
p
valu
deviat
expect
rank
term
base
input
random
gene
set
enrich
adjust
p
valu
present
webgestalt
use
background
gene
list
correct
corum
comprehens
resourc
mammalian
protein
complex
gobp
gene
ontolog
biolog
process
abbrevi
tabl
embryo
zebrafish
select
gene
knockdown
abil
surviv
via
oxygen
diffus
absenc
function
cardiovascular
system
permit
studi
lethal
cardiac
defect
later
develop
use
crisprguid
knockdown
observ
cardiac
phenotyp
embryo
mosaic
loss
tabl
revers
cardiac
loop
observ
knockdown
embryo
knockdown
result
zebrafish
embryo
small
poorli
contractil
ventricl
often
gene
associ
consist
enrich
term
previous
implic
structur
heart
defect
strongli
connect
edward
et
al
associ
atrial
dilat
figur
notabl
gene
highli
express
develop
heart
brain
mous
brain
phenotyp
observ
knockdown
embryo
direct
link
planar
cell
polar
complex
signal
rhogtpas
earli
lethal
prohibit
studi
global
loss
second
heart
fieldspecif
knockdown
taken
togeth
studi
illustr
alter
signal
via
planar
cell
disrupt
normal
mammalian
heart
develop
addit
contribut
small
gtpasemedi
signal
loss
may
also
contribut
chd
role
ubiquitin
cell
regul
edward
et
al
anoth
potenti
import
advantag
silico
test
potenti
identifi
area
rescu
repurpos
exist
drug
rescu
refer
redirect
drug
alreadi
fail
efficaci
trial
one
applic
success
engin
construct
heart
muscl
permit
measur
virtual
paramet
heart
function
includ
twitch
forc
kinet
beat
rate
rhythm
diastol
tension
intracellular
calcium
movement
engin
cardiac
tissu
potenti
use
research
tool
replac
anim
toxic
test
therapeut
agent
therapi
unto
model
easi
manipul
genet
behav
quantit
much
like
nativ
muscl
make
reason
platform
diseas
model
toxic
test
exampl
truitt
et
al
bear
mind
drug
fda
regulatori
bodi
agre
allow
oc
technolog
replac
phase
anim
test
technolog
proven
least
accur
current
test
earli
data
scarc
promis
pulmonari
edema
model
creat
oc
respons
lowmolecularweight
pulmonari
edema
therapeut
shown
similar
oc
result
obtain
anim
model
inspheroag
medicin
agenc
also
put
forth
guidelin
elimin
significantli
restrict
anim
test
certain
human
medicin
product
order
reduc
anim
use
drug
regulatori
approv
vascular
calcif
highli
regul
cellmedi
process
strongli
associ
ckd
confer
increas
risk
incid
cv
event
multipl
pathway
link
vascular
calcif
ckd
howev
remain
incomplet
understood
develop
target
therapi
underwhelm
illumin
causal
step
natur
histori
link
vascular
calcif
cv
event
affirm
role
cv
risk
factor
acceler
drug
discoveri
therapeut
translat
global
burden
kidney
diseas
continu
rise
context
cardiovascular
diseas
cvd
signific
contributor
high
morbid
experienc
patient
ckd
cv
death
common
caus
death
popul
figur
shown
linear
relat
cv
mortal
reduc
egfr
proteinuria
albuminuria
effect
pronounc
endstag
kidney
diseas
eskd
adult
commenc
dialysi
older
year
age
form
cvd
experi
rel
risk
cv
death
exce
time
gener
popul
adult
younger
year
age
rel
risk
even
dramat
incid
eskd
confer
risk
cv
death
compar
agematch
popul
express
anoth
way
person
mild
moder
stage
ckd
higher
risk
cv
event
cv
mortal
progress
eskd
ckd
impart
increas
risk
wide
array
cvd
figur
although
atherosclerot
cvd
frequent
manifest
lead
consid
ckd
coronaryarteri
risk
equival
rate
heart
failur
stroke
valvular
heart
diseas
arrhythmia
sudden
cardiac
death
figur
find
observ
patient
higher
equal
stage
ckd
provid
mechanist
basi
increas
rate
heart
failur
atrial
fibril
observ
ckd
vhd
valvular
heart
diseas
abbrevi
figur
view
later
lumbar
spine
plane
radiograph
although
score
reason
interobserv
reproduc
progress
reduct
p
r
l
vascular
calcif
carotid
vessel
associ
increas
risk
stroke
involv
proxim
aorta
caus
porcelain
aorta
prohibit
cardiothorac
surgeri
calcif
coronari
arteri
link
increas
cardiovascular
allcaus
mortal
local
may
caus
increas
atherothrombosi
calcif
aorta
distal
vessel
associ
increas
arteri
stiff
calcif
iliofemor
vessel
site
anastomosi
associ
graft
failur
wors
transplant
outcom
calcif
radial
arteri
fistula
site
gener
associ
earli
fistula
failur
calcif
lower
limb
arteri
associ
develop
peripher
arteri
diseas
pad
claudic
limb
ischemia
well
arteri
stiff
calciphylaxi
sever
acceler
form
calcif
predominantli
local
medial
layer
skin
arteriol
commonli
affect
lower
limb
occur
anywher
cac
coronari
arteri
calcif
regard
patholog
tightli
regul
cellmedi
process
resembl
bone
format
turnov
despit
growth
understand
tempor
sequenc
event
exact
cellular
step
remain
incomplet
understood
focu
ongo
research
moreov
observ
event
unlik
occur
stepwis
manner
instead
like
repres
synchron
interrel
process
tabl
support
data
patient
ckd
suggest
level
fetuina
invers
associ
vascular
calcif
low
level
link
inflamm
allcaus
mortal
dialysi
popul
mgp
wide
express
protein
shown
accumul
calcifi
tissu
precis
role
remain
unconfirm
howev
two
prevail
potenti
synergist
theori
mgp
may
bind
calcium
ion
calcium
crystal
therebi
inhibit
crystal
growth
mgp
may
interfer
bone
morphogen
protein
signal
prevent
unwant
cellinduc
miner
anim
mgpknockout
model
develop
rapid
extens
aortic
medial
calcif
associ
ruptur
earli
hemorrhag
death
vitro
studi
show
mgp
etelcalcetid
intraven
calcimimet
act
differ
site
car
highli
efficaci
lower
pth
placebocontrol
trial
headtohead
studi
effect
cinacalcet
biochem
endpoint
effect
etelcalcetid
vascular
calcif
clinic
event
evalu
vitamin
k
previous
describ
vitamin
k
requir
decarboxyl
mgp
obtain
calcif
inhibitori
capac
consist
physiolog
vitamin
k
antagon
vitamin
k
defici
link
vascular
calcif
biochem
proofofconcept
studi
conduct
patient
underw
hemodialysi
daili
supplement
vitamin
k
safe
result
signific
increas
mgp
activ
whether
increas
mgp
activ
translat
slow
calcif
test
vitavask
studi
trial
enrol
patient
underw
hemodialysi
cac
score
least
random
either
oral
vitamin
oral
thrice
weekli
supplement
placebo
open
label
trial
halt
earli
includ
particip
larger
studi
requir
confirm
progress
find
combin
predominantli
intim
versu
predominantli
medial
modal
provid
uniqu
insight
natur
histori
rel
modifi
potenti
differenti
drug
efficaci
furthermor
convent
think
vascular
calcif
rel
unidimension
aim
restor
revers
compon
urem
milieu
individu
calcif
establish
inhibitori
mechan
exhaust
underwhelm
result
may
due
late
inter
nelson
et
al
